loading

Dechra Pharmaceuticals PLC

Overview

Welcome to Dechra's 2020 Annual Report
Chairman's View
Dechra's Strengths
Highlights
Our Purpose and Strategy
Our Geographical Footprint

Strategic Report

Delivering Our Purpose
Our Marketplace
Global Market Dynamics
Product Market Dynamics
Our Business Model
Creating Value For Our Stakeholders
Delivering Our Strategy
Overview
Our Achievements and Progress
Chief Executive Officer's Statement
Financial Review
Key Performance Indicators
Strategy in Action
People
Technology
Manufacturing and Supply Chain
Product Development
Product Development Process
Product Development Pipeline
International Product Offering
Section 172 Statement
Corporate Social Responsibility
Overview
Our People
Our Environment
Our Business
Our Community
Non-Financial Information Statement
How the Business Manages Risk
Overview
Understanding Our Key Risks
Viability Statement

Governance

Delivering Our Purpose
Letter from the Chairman on Governance
Corporate Governance
Board of Directors
Senior Executive Team
Non-Executive Directors
Board Leadership and Company Purpose
Division of Responsibilities
Composition, Succession and Evaluation
Audit, Risk and Internal Control
Directors' Remuneration Report
Letter from the Remuneration Committee Chairman
Directors' Remuneration Policy
2020 Annual Report on Remuneration
Directors' Report Other Disclosures
Statement of Directors' Responsibilities

Financial Statements

Independent Auditors' Report to the Members of Dechra Pharmaceuticals PLC
Consolidated Income Statement
Consolidated Statement of Comprehensive Income
Consolidated Statement of Financial Position
Consolidated Statement of Changes in Shareholders' Equity
Consolidated Statement of Cash Flows
Notes to the Consolidated Financial Statements
Company Statement of Financial Position
Company Statement of Changes in Shareholders' Equity
Notes to the Company Financial Statements
Financial History

Company Information

Delivering Our Purpose
Glossary
Shareholder Information
Advisers

Annual Report and Accounts for the year ended 30 June 2020

Financials-new
  • Home
  • Financial Statements
  • Notes to the Consolidated Financial Statements
  • 18. Cash and Cash Equivalents

18. Cash and Cash Equivalents

2020
£m		2019
£m
Cash at bank and in hand227.480.3
  • previous 17. Trade and Other Receivables
  • next 19. Trade and Other Payables
  • Overview
  • Strategic Report
  • Governance
  • Financial Statements
  • Company Information

©2020 Dechra Pharmaceuticals PLC

www.dechra.com
  • Site Map
  • Accessibility
  • Cookies

Powered by jonesandpalmer.co.uk